{
    "id": 1467,
    "fullName": "EGFR L747S",
    "impact": "missense",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "EGFR L747S lies within the protein kinase domain of the Egfr protein (UniProt.org). L747S is predicted to lead to a gain of function as indicated by increased transformation ability compared to wild-type Egfr in two different cell lines in one study (PMID: 29533785), and is associated with resistance to Egfr tyrosine kinase inhibitors (PMID: 24396447).",
            "references": [
                {
                    "id": 11238,
                    "pubMedId": 29533785,
                    "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 12173,
                    "pubMedId": 24396447,
                    "title": "Acquired resistance L747S mutation in an epidermal growth factor receptor-tyrosine kinase inhibitor-na\u00efve patient: A report of three cases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24396447"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "L747S",
    "createDate": "08/20/2014",
    "updateDate": "09/11/2018",
    "referenceTranscriptCoordinates": {
        "id": 135747,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55174777T>C",
        "cDna": "c.2240T>C",
        "protein": "p.L747S",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 14704,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR L747S were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).",
            "molecularProfile": {
                "id": 1492,
                "profileName": "EGFR L747S"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14699,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR L747S were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).",
            "molecularProfile": {
                "id": 1492,
                "profileName": "EGFR L747S"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14701,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR L747S were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).",
            "molecularProfile": {
                "id": 1492,
                "profileName": "EGFR L747S"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3057,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L858R that had developed Iressa (gefitinib) resistance after an initial response was demonstrated to have acquired an EGFR L747S mutation (PMID: 18981003).",
            "molecularProfile": {
                "id": 11382,
                "profileName": "EGFR L747S EGFR L858R"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 3591,
                    "pubMedId": 18981003,
                    "title": "Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18981003"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3058,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L858R and EGFR L747S had an initial partial response to Tarceva (erlotinib), but was found to progress after 6 months (PMID: 18981003).",
            "molecularProfile": {
                "id": 11382,
                "profileName": "EGFR L747S EGFR L858R"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3591,
                    "pubMedId": 18981003,
                    "title": "Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18981003"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1492,
            "profileName": "EGFR L747S",
            "profileTreatmentApproaches": [
                {
                    "id": 17909,
                    "name": "EGFR Inhibitor (Pan)",
                    "profileName": "EGFR L747S"
                },
                {
                    "id": 17908,
                    "name": "EGFR Inhibitor 3rd gen",
                    "profileName": "EGFR L747S"
                },
                {
                    "id": 17907,
                    "name": "HER inhibitor (Pan)",
                    "profileName": "EGFR L747S"
                },
                {
                    "id": 17911,
                    "name": "EGFR Inhibitor 2nd gen",
                    "profileName": "EGFR L747S"
                },
                {
                    "id": 17910,
                    "name": "EGFR Inhibitor 1st gen",
                    "profileName": "EGFR L747S"
                }
            ]
        },
        {
            "id": 11382,
            "profileName": "EGFR L747S EGFR L858R",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 135747,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55174777T>C",
            "cDna": "c.2240T>C",
            "protein": "p.L747S",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}